7 active not recruiting, 7 recruiting, 1 not yet recruiting, 1 terminated. 16 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Active not recruiting 7, Recruiting 7, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 9 | Active not recruiting 5, Recruiting 3, Terminated 1 |
Follow Epcoritamab: new trials by email Literature Review of Epcoritamab trials Research Report on Epcoritamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL Epcoritamab, Glofitamab, External Beam Radiation Therapy - Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | University of Utah | 12 | 2026-06-01 | 2026-06-04 |
| A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) ibrutinib, Epcoritamab - Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2025-08-13 | 2026-07-14 |
| Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome epcoritamab - Leukemia, Chronic Lymphocytic, Richter Syndrome | Phase 1 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 5 | 2025-07-18 | 2026-11-09 |
| Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders Biopsy, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder | Phase 1 | Recruiting | Timothy Voorhees | 26 | 2025-06-16 | 2026-09-24 |
| Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Recruiting | Yazeed Sawalha | 38 | 2025-04-02 | 2026-08-25 |
| Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab Siltuximab, Epcoritamab, Gemcitabine and oxaliplatin - Non-Hodgkin Lymphoma, Cytokine Release Syndrome | Phase 1 | Recruiting | Taylor Brooks | 20 | 2025-01-14 | 2026-06-25 |
| Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL Epcoritamab, Venetoclax - CLL/SLL | Phase 1 / Phase 2 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 112 | 2024-04-15 | 2026-10-05 |
| A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas BMS-986458, Rituximab, Glofitamab/Obinutuzumab - Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Bristol-Myers Squibb | 460 | 2023-12-29 | 2026-10-23 |
| Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab Epcoritamab - Non-hodgkin Lymphoma | Phase 1 | Active not recruiting | Genmab | 17 | 2022-10-04 | 2026-09-11 |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma Epcoritamab, Cyclophosphamide, Rituximab - B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Genmab | 49 | 2022-03-10 | 2026-11-04 |
| Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax - Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Genmab | 194 | 2020-11-25 | 2026-11-04 |
| Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Genmab | 543 | 2020-11-03 | 2026-11-03 |
| Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) Epcoritamab (monotherapy), Epcoritamab, Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Genmab | 78 | 2020-08-20 | 2026-11-04 |
| First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas GEN3009, Epcoritamab - Diffuse Large B-cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Terminated | Genmab | 46 | 2020-03-13 | 2024-10-24 |
| First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma Epcoritamab - DLBCL, High-grade B-cell Lymphoma (HGBCL) | Phase 1 / Phase 2 | Active not recruiting | Genmab | 666 | 2018-06-26 | 2026-11-04 |
Lymphoma, Large B-Cell, Diffuse (7) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Follicular (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma, B-Cell (2) · Neoplasms (2) · Cytokine Release Syndrome (1) · Leukemia (1) · Lymphoma, Mantle-Cell (1) · Recurrence (1)
Genmab (7) · Bristol-Myers Squibb (1) · Jonsson Comprehensive Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · Taylor Brooks (1) · Timothy Voorhees (1) · University of Utah (1) · Yazeed Sawalha (1)
United States (13) · Netherlands (6) · Spain (6) · Australia (5) · Belgium (5) · Denmark (5) · France (5) · Germany (5) · Italy (5) · Czechia (3) · Japan (3) · South Korea (3) · United Kingdom (3) · Canada (2) · China (2)
Adrian U Wiestner, M.D. (1) · Christian Grommes, MD (1) · Sven De Vos (1) · Taylor Brooks, MD (1) · Timothy J Voorhees, MD (1) · Yazeed Sawalha (1)
PMID 42411504, PMID 42541678, PMID 34508654, PMID 36548927, PMID 38151388, PMID 38889737, PMID 39322711, PMID 39792928, PMID 40472301, PMID 40632620, PMID 40920572, PMID 41380698, PMID 41670385, PMID 41784015, PMID 42431612, PMID 42622258, PMID 42660129
2023 (4), 2017 (1), 2019 (1), R01CA308586 (1)